NDA 211039 · Bausch Lomb Ireland
Fluorescein Sodium and Benoxinate Hydrochloride
Benoxinate Hydrochloride, Fluorescein Sodium · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Mar 9, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Mar 9, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
4 Phase 3, 2 recruiting
FAERS reports
3
3 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 12, 2025.
Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a combination of fluorescein sodium, a disclosing agent and benoxinate hydrochloride, a local ester anesthetic indicated for procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic. ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE · BENOXINATE HYDROCHLORIDE 0.4%; FLUORESCEIN SODIUM 0.3% · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Benoxinate" as an intervention, any sponsor and status, largest first.
Valenta Pharm JSCIndustry
NCT06843018 · 300 participants (planned) · Start Nov 14, 2024 · Primary completion Dec 31, 2026
Drug: Grammidin with anesthetic; Septolete Total · For: Pharyngitis Acute; Pharyngitis; Nasopharyngitis and 1 more
Sites: Engel's, Russia; Kaliningrad, Russia; Moscow, Russia · 12 sites in all
- VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High MyopiaCompleted
London Vision ClinicAcademic, hospital or other
NCT02528123 · 114 participants · Start Apr 2016 · Primary completion Dec 7, 2020
Drug: Tobramycin and dexamethasone; Ofloxacin and 2 more · For: Myopia; Refractive Errors
Sites: London, United Kingdom
- Conscious Sedation for Cataract Operations Under Topical AnaesthesiaPivotal-lookingCompleted
Menoufia UniversityAcademic, hospital or other
NCT03933280 · 100 participants · Start Jul 1, 2019 · Primary completion Dec 1, 2020
Drug: Nalbuphine; Propofol and 2 more · For: Conscious Sedation
Sites: Cairo, Egypt
- Bupivacaine vs Oxybuprocaine Topical Anesthesia in IVIPivotal-lookingCompleted
Research Institute of Ophthalmology, EgyptAcademic, hospital or other
NCT05069350 · 100 participants · Start Sep 1, 2021 · Primary completion Aug 1, 2022
Drug: bupivacaine 0.5% and oxubuprocaine · For: Pain, Acute
Sites: Giza, Egypt
- Effect of Benoxinate Hydrochloride Eye Drops on The Premature Infant Pain Profile Score During Retinopathy of Prematurity ScreeningPivotal-lookingCompleted
Alexandria UniversityAcademic, hospital or other
NCT06461975 · 88 participants · Start Jan 1, 2023 · Primary completion Apr 30, 2023
Drug: Benoxinate Hydrochloride; artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops. · For: Retinopathy of Prematurity
Sites: Alexandria, Egypt
- Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric PopulationPivotal-lookingCompleted
Sintetica SAIndustry
NCT05926258 · 74 participants · Start May 23, 2024 · Primary completion Mar 13, 2025
Drug: Chloroprocaine 3% eye gel; Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops · For: Local Anesthetic
Sites: Milan, Italy; Verona, Italy · 3 sites in all
Assiut UniversityAcademic, hospital or other
NCT05733741 · 70 participants · Start Jan 30, 2023 · Primary completion Apr 15, 2023
Drug: Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt); Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt). · For: Myopia
Sites: Asyut, Egypt
Alexandria UniversityAcademic, hospital or other
NCT05666362 · 68 participants · Start Jan 20, 2023 · Primary completion Dec 20, 2024
Drug: benoxinate hydrochloride 0.4% group; saline 0.9% . · For: Preterm
Sites: Alexandria, Egypt
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- syncope2
- abdominal pain upper1
- blood glucose decreased1
- confusional state1
- disorientation1
- dizziness1
- dysarthria1
- dyspnoea1
- fatigue1
- feeling hot1
- headache1
- heart rate increased1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2019 | 1 |
| 2024 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effect of mydriasis from phenylephrine on corneal shape.
Huang RY, Lam AK · Clin Exp Optom 2007 · Randomized Controlled Trial
- Comparative clinical trial of topical anesthetic agents in cataract surgery: lidocaine 2% gel, bupivacaine 0.5% drops, and benoxinate 0.4% drops.
Soliman MM, Macky TA, Samir MK · J Cataract Refract Surg 2004 · Clinical Trial, Comparative Study
- A comparison of Fluoracaine and Fluorox on corneal epithelial cell desquamation after Goldmann Applanation Tonometry.
Yeung KK, Kageyama JY, Carnevali T · Optometry 2000 · Clinical Trial, Comparative Study
- Degree of corneal anesthesia after topical application of 0.4% oxybuprocaine ophthalmic solution in normal equids.
Little E, Yvorchuk-St Jean K, Little W, et al. · Can J Vet Res 2016 · Randomized Controlled Trial
- Anesthetic effects from low concentrations of proparacaine and benoxinate.
Jauregui MJ, Sanders TJ, Polse KA · J Am Optom Assoc 1980 · Clinical Trial, Controlled Clinical Trial
- Comparison of the tolerability and efficacy of unit-dose, preservative-free topical ocular anaesthetics.
Lawrenson JG, Edgar DF, Tanna GK, et al. · Ophthalmic Physiol Opt 1998 · Clinical Trial, Comparative Study
Sponsor: Bausch Lomb Ireland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.